Interactive Brokers Appointed International Broker for Sinopac Securities
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced its appointment as the primary international broker for Sinopac Securities today. Institutional and retail clients of Sinopac can trade US stocks, ETFs, and Fixed Income instruments while also accessing over 90 stock markets worldwide through Interactive Brokers. This initiative between Interactive Brokers LLC and Sinopac strengthens Interactive Brokers’ footprint in the APAC region and adds Taiwan to the over 200 countries and territories worldwide where the company services clients.
“We are pleased to work with Sinopac and bring Interactive Brokers’ global trading capabilities and expertise to Taiwan,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “We recognize the advantage of working with a leading broker with local experience and look forward to serving the needs of this important market and its investors.”
Taiwanese investors will benefit from Interactive Brokers’ powerful trading platforms and advanced technology and tools. Interactive Brokers offers clients the ability to trade fractional shares of eligible US and European stocks as well as ETFs and can accommodate over 100 order types, including algorithmic trading, which is currently unavailable through other brokers in Taiwan. Clients can trade select US ETFs 23½ hours a day, five days a week through Overnight Trading Hours on the IBKR Eos ATS (“IBEOS”). With Overnight Trading Hours, investors across Asia can access US Equity Markets during their trading day and respond to market-moving news at almost any time. The collaboration with Sinopac also enables clients of Interactive Brokers to trade Taiwanese stocks through Sinopac Securities.
Introducing Brokers worldwide use Interactive Brokers’ Prime Broker services to help manage their businesses with efficiency and serve their clients at a lower cost. Through Interactive Brokers, Introducing Brokers can reduce their operational, brokerage, and clearing costs while gaining electronic market access worldwide with the company’s professional, white-branded trading technology. Interactive Brokers’ turnkey solution covers trading, clearing, reporting, and billing and provides the following advantages:
- Support for global regulatory reporting
- Account funding and trading in up to 26 currencies
- Access to stocks, options, futures, currencies, bonds, and funds in over 150 markets from a single unified platform
- No ticket charges, no minimums, and no technology, software, platform, or reporting fees
- Free client relationship management tools
For additional information about Interactive Brokers’ Introducing Broker platform, please visit:
US and Countries Served by IB LLC: https://www.interactivebrokers.com/en/accounts/broker.php
Canada: https://www.interactivebrokers.ca/en/accounts/broker.php
UK: https://www.interactivebrokers.co.uk/en/accounts/broker.php
Western Europe: https://www.interactivebrokers.ie/en/accounts/broker-ie.php
Central Europe: https://www.interactivebrokers.hu/en/accounts/broker-hu.php
Hong Kong: https://www.interactivebrokers.com.hk/en/accounts/broker.php
Singapore: https://www.interactivebrokers.com.sg/en/accounts/broker.php
India: https://www.interactivebrokers.co.in/en/accounts/broker.php
Australia: https://www.interactivebrokers.com.au/en/accounts/broker.php
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 150 markets in numerous countries and currencies from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005686/en/
Contact information
Interactive Brokers Group, Inc
Katherine Ewert, media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
